AN2 Therapeutics, Inc. (NASDAQ: ANTX) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT AN2 THERAPEUTICS, INC.

AN2 Therapeutics, Inc. (NASDAQ: ANTX)
Listen to this Section


$4.88
+0.0830 ( +1.73% ) 127.9K

AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.

Market Data


Open $4.88
Previous Close $4.80
Volume 127.9K
Market Cap $172.88M
Day Range $4.63 - $5.06
52 Week Range $1.00 - $6.91
Shares Outstanding 36.02M
Change % +1.73%
Net Change ▲ 0.0830
Insider Ownership -0.18%
Exchange NASDAQ
SectorMiscellaneous
IndustryNone
IPO Year2022
CountryUnited States
UnderwriterTD Cowen, Leerink Partners, Evercore ISI, Oppenheimer & Co., more

Insider Ownership Transactions

Total Amount Purchased: -1,219,102.00

Date Type Amount Purchased Purchaser
2024-01-11 Sale -2417.00 Krause Kevin Michael
2024-01-04 Sale -2583.00 Krause Kevin Michael
2024-01-04 Sale -2777.00 Easom Eric
2023-11-16 Sale -1522.00 Aziz Kabeer
2023-11-16 Sale -1522.00 Adjuvant Global Health Technology Fund, L.P.
2023-10-03 Sale -83337.00 Aziz Kabeer
2023-10-03 Sale -83337.00 Adjuvant Global Health Technology Fund, L.P.
2023-09-29 Sale -707.00 Adjuvant Global Health Technology Fund, L.P.
2023-09-29 Sale -707.00 Aziz Kabeer
2023-09-15 Sale -336.00 Aziz Kabeer

SEC Filings


Form Type Description Pages Date
10-q Quarterly Reports 60 Nov 12, 2025
8-k 8K-related 11 Nov 12, 2025
4 Insider transactions 1 Nov 06, 2025
4 Insider transactions 1 Nov 06, 2025
4 Insider transactions 1 Oct 14, 2025
4 Insider transactions 1 Oct 14, 2025
4 Insider transactions 1 Oct 14, 2025
8-k 8K-related 11 Aug 12, 2025
10-q Quarterly Reports 61 Aug 12, 2025
4 Insider transactions 1 Jul 11, 2025

Latest News